Chemomab Therapeutics - רווח לפני ניכוי ריבית, מסים, בלאי ופחת CMMB

Chemomab Therapeutics (CMMB) is implementing ESG principles by reducing chemical waste during the development of fibrosis treatments. This EBITDA trend on the current GURU.Markets chart shows that 0.00 is the current metric value. However, financial stability is limited by the risk of failed trials, and a high dependence on a single drug in the portfolio creates a serious vulnerability in the business model.

An investment audit of Chemomab Therapeutics (CMMB) requires an analysis of actual commercial cash flows to assess business viability. This metric captures daily operating income adjusted for non-cash charges, which, in a biotech environment with a minimal ecological footprint and costs limited to waste disposal, allows the EBITDA trend to differentiate seasonal fluctuations from a systemic crisis.